¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á(CGT) ¿¬±¸ÀÇ Àü¸Á ¹× ±â¼úÀÇ ¼ºÀå ±âȸ
CGT Research Outlook and Technology Growth Opportunities
»óǰÄÚµå : 1540741
¸®¼­Ä¡»ç : Frost & Sullivan
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 76 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,859,000
Web Access (Regional License) help
Frost & SullivanÀÇ À¥»çÀÌÆ® ·Î±×ÀÎ ÆÐ½º¿öµå°¡ ¹ßÇàµÇ¸ç, PDF¸¦ ´Ù¿î·Îµå ¹Þ´Â ÇüÅ·ΠÁ¦°øµÉ ¿¹Á¤ÀÔ´Ï´Ù. PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ ¸ðµç ºÐµéÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


Çѱ۸ñÂ÷

CGT »óȲ Æò°¡

CGT¸¦ µÑ·¯½Ñ ȯ°æÀº Áö³­ 10³â°£ Å©°Ô ÁøÈ­ÇØ ¿Ô½À´Ï´Ù. ¼¼°è¿¡¼­´Â 80°³°¡ ³Ñ´Â CGT Á¦Ç°ÀÌ »ó¾÷È­µÇ°í ÀÖÀ¸¸ç, 2023³â¿¡¸¸ 34°³ÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·áÁ¦°¡ FDA ½ÂÀÎÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Á¦Ç° ÆÄÀÌÇÁ¶óÀΰú ÀÓ»ó ¼º°ø·üÀÌ ³ô¾ÆÁü¿¡ µû¶ó »õ·Î¿î ±â¼ú Ç÷§ÆûÀÇ °³¹ß, Á¦Á¶ ´É·Â ¹× »õ·Î¿î Áúº´ ¿µ¿ªÀ¸·ÎÀÇ È®´ë¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

Áö³­ 5³â°£ ƯÇã »óȲ, ÅõÀÚ »óȲ, ÀÓ»ó½ÃÇè ºÐ¾ß´Â Áö¼ÓÀûÀÎ ¼ºÀå°ú Ȱµ¿À» °è¼ÓÇØ ¿Ô½À´Ï´Ù. ÀÌ ¼¼ °¡Áö ºÎ¹®Àº ¸ðµÎ CGTÀÇ ¼ºÀå¿¡ Å©°Ô ±â¿©Çϸç CGTÀÇ ¹Ì·¡¿¡ ´ëÇÑ À¯¸ÁÇÑ ÀáÀç·ÂÀ» º¸¿©ÁÝ´Ï´Ù. CGTÀÇ »óȲ¿¡´Â ¼¼Æ÷ ¿ä¹ý, À¯ÀüÀÚ ¿ä¹ý, À¯ÀüÀÚ º¯Çü ¼¼Æ÷ ¿ä¹ýÀÇ ¼¼ °¡Áö ÁÖ¿ä ¹üÁÖ°¡ ÀÖ½À´Ï´Ù. CAR-T³ª CAR-NK¿Í °°Àº À¯ÀüÀÚº¯Çü ¼¼Æ÷¿ä¹ýÀº ÆÄÀÌÇÁ¶óÀο¡ ÀÖ´Â ÀÓ»ó ÇÁ·Î±×·¥ÀÇ ¼ö°¡ ¸¹¾Æ ÇâÈÄ ¼ö³â°£ ³ôÀº ÀÓ»ó È¿°ú°¡ ±â´ëµË´Ï´Ù.

CGTÀÇ °³¹ßÀÚ´Â Ç÷¾× ÁúȯÀ̳ª Á¾¾ç À̿ܿ¡µµ ´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ½Å°æ Áúȯ µî »õ·Î¿î Áúȯ ¿µ¿ªÀ» °³Ã´Çϰí ÀÖ¾î CGT ¼ö¿ä¸¦ ²ø¾î¿Ã¸± °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

ÀÌ º¸°í¼­´Â CGTÀÇ °³¹ß »óȲ°ú µ¿Çâ¿¡ ´ëÇØ ´Ù·ì´Ï´Ù. CGT¸¦ °³¼±Çϱâ À§ÇÑ ½Å±â¼úÀÇ °í¿ëÀ» º¸¿©ÁÖ´Â Çù·ÂÀûÀΠȯ°æÀº CGTÀÇ °³¹ß°ú Á¦Á¶¿¡¼­ ¿£µå Åõ ¿£µåÀÇ ´É·ÂÀ» º¯È­½Ãŵ´Ï´Ù.

º¤ÅÍ ¼³°è, ¼¼Æ÷ÁÖ Á¦Á¶, CGT Á¦Á¶ ´É·ÂÀÇ µðÁöÅÐÈ­, ¿£µå Åõ ¿£µå CGT °³¹ß Àü¹Ý¿¡ °ÉÃÄ AI ÅëÇÕ¿¡ °üÇÑ ±â¼úÀÇ ÀϰüµÈ °³¹ß·Î ƯÇã Ȱµ¿Àº ³ôÀº ¼öÁØ¿¡ ÀÖ½À´Ï´Ù. º¥Ã³Ä³ÇÇÅ»Àº ÇâÈÄ ¼ö³â°£ CGT ºÐ¾ß¿¡ Å« °¡´É¼ºÀÌ ÀÖ´Ù°í º¸°í ÀÖÀ¸¸ç, ½ÅÈï±â¾÷°ú Áß°ß CGT °³¹ß±â¾÷À» Áö¿øÇÏ¿© ÆÄÀÌÇÁ¶óÀÎÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÇâÈÄ ¼ö³â°£ ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ» ¹Þ´Â CGTÀÇ ¼ö´Â 3¹è°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµÇ¾î ȯÀÚÀÇ Á¢±Ù¼ºÀ» ³ôÀ̱â À§ÇÑ Á¤Ã¥ÀÌ ½Ç½ÃµÉ ¿¹Á¤ÀÔ´Ï´Ù.

¸ñÂ÷

Àü·«Àû °úÁ¦

¼ºÀå ±âȸ ºÐ¼®

¼ºÀå ¿äÀÎ

CGT ƯÇ㠺м®

CGT ÅõÀÚ »óȲ

CGT ÃâÆÇ µ¿Çâ

¹ë·ùüÀÎÀÇ ¿¬±¸ °³¹ß Àü¸Á

CGT ÀÓ»ó½ÃÇè »óȲ

CGTÀÇ ¼ºÀå ±âȸ

ºÎ·Ï

´ÙÀ½ ´Ü°è

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

CGT Landscape Assessment

The CGT landscape has evolved extensively over the past decade. More than 80 CGT products have been commercialized globally, with 34 FDA-approved cell and gene therapies in 2023 alone. The rise in product pipelines and clinical success rates has led to the growing demand for the development of new technology platforms, manufacturing capabilities, and expansion to new disease areas.

Over the past five years, the patent landscape, investment landscape, and clinical trial segment have had consistent growth and activity. All three segments contribute extensively to the growth of CGTs and showcase the promising potential of CGTs for the future. The CGT landscape has three main categories of therapies: cell therapies, gene therapies, and gene-modified cell therapies, with all three progressing well over the past years. Gene-modified cell therapies, such as CAR-T and CAR-NK, have a higher number of clinical programs in the pipeline and are expected to have a high clinical impact in the coming years.

CGT developers are exploring new disease areas, apart from hematological conditions and oncology, to include diabetes, cardiovascular diseases, and neurological conditions, which will boost the demand for CGTs.

The report covers the developments and trends in the CGT landscape. A collaborative environment showing the high adoption of new technologies to improve CGTs will transform the end-to-end capabilities in CGT development and manufacturing.

Patent activity is high because of consistent developments in technology for vector design, cell line manufacturing, digitalization of CGT manufacturing capabilities, and AI integration across the end-to-end CGT development. Venture capital firms see huge potential in the CGT segment in the coming years and have been constant supporters in backing start-ups and mid-sized CGT developers to accelerate their pipelines. In the coming years, the number of CGTs receiving regulatory approvals is predicted to multiply by three fold, and policies will be put in place to increase patient accessibility.

Table of Contents

Strategic Imperatives

Growth Opportunity Analysis

Growth Generator

CGT Patent Analysis

CGT Investment Landscape

CGT Publication Trend

R&D Outlook across the Value Chain

CGT Clinical Trial Landscape

Growth Opportunity Universe in CGT

Appendix

Next Steps

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â